Raffaele Marfella
Overview
Explore the profile of Raffaele Marfella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
9109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fumagalli C, Maurer M, Fontana M, Fine N, Gillmore J, Goyal P, et al.
JACC Adv
. 2024 Aug;
3(9):101123.
PMID: 39140080
Transthyretin cardiac amyloidosis (ATTR-CA) predominantly affects older adults with multiple chronic conditions, leading to significant physical, cognitive, and emotional challenges. New disease-modifying drugs are effective in early stages, prompting a...
12.
Caturano A, Galiero R, Vetrano E, Sardu C, Rinaldi L, Russo V, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125938
Insulin signaling is vital for regulating cellular metabolism, growth, and survival pathways, particularly in tissues such as adipose, skeletal muscle, liver, and brain. Its role in the heart, however, is...
13.
Caturano A, Russo V, Monda M, Sardu C, Marfella R, Sasso F
J Cardiovasc Pharmacol
. 2024 Aug;
84(5):493-495.
PMID: 39115821
No abstract available.
14.
Minutolo R, Simeon V, De Nicola L, Chiodini P, Galiero R, Rinaldi L, et al.
Cardiovasc Diabetol
. 2024 Aug;
23(1):285.
PMID: 39103870
Objective: Women with type 2 diabetes experience higher cardiovascular and mortality risk than men possibly because of a sub-optimal cardio-protective treatment. We evaluated whether an intensive multifactorial therapy (MT) produces...
15.
Caturano A, Vetrano E, Galiero R, Salvatore T, Docimo G, Epifani R, et al.
Rev Cardiovasc Med
. 2024 Jul;
23(5):165.
PMID: 39077592
Cardiac hypertrophy develops in response to increased workload to reduce ventricular wall stress and maintain function and efficiency. Pathological hypertrophy can be adaptive at the beginning. However, if the stimulus...
16.
Caturano A, Nilo R, Nilo D, Russo V, Santonastaso E, Galiero R, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065795
Diabetes mellitus, which comprises a group of metabolic disorders affecting carbohydrate metabolism, is characterized by improper glucose utilization and excessive production, leading to hyperglycemia. The global prevalence of diabetes is...
17.
Barbieri M, Prattichizzo F, La Grotta R, Matacchione G, Scisciola L, Fontanella R, et al.
Ageing Res Rev
. 2024 Jul;
99:102405.
PMID: 38971321
Diabetes mellitus, a metabolic condition affecting around 537 million individuals worldwide, poses significant challenges, particularly among the elderly population. The etiopathogenesis of type 2 diabetes (T2D) depends on a combination...
18.
Sardu C, Vittoria Marfella L, Giordano V, Lepre C, DAmico G, Volpicelli M, et al.
Front Pharmacol
. 2024 Jun;
15:1402782.
PMID: 38835659
Background: Left bundle branch (LBB) pacing could achieve cardiac resynchronization therapy (CRT) in patients who cannot be resynchronized via the placement of the left ventricle (LV) lead into the coronary...
19.
Anastasio C, Donisi I, Del Vecchio V, Colloca A, Mele L, Sardu C, et al.
Cell Mol Biol Lett
. 2024 May;
29(1):80.
PMID: 38811901
Background: Sodium-glucose transporter 2 (SGLT2) inhibitors (iSGLT2) are approved medications for type 2 diabetes. Recent studies indicate that iSGLT2 inhibit the growth of some cancer cells. However, the mechanism(s) remains...
20.
Marfella R, Prattichizzo F
N Engl J Med
. 2024 May;
390(18):1728.
PMID: 38718368
No abstract available.